此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Immune Monitoring Following B-cell Depletion in ANCA-associated Vasculitis (NALVANCA)

2026年7月3日 更新者:Nantes University Hospital

NALVANCA: Immune Monitoring Following B-cell Depletion in ANCA-associated Vasculitis

ANCA-associated vasculitis is a serious autoimmune disease. The standard treatment is rituximab (RTX), which depletes B-cells to control inflammation. However, identifying patients at high risk of relapse remains a challenge, often leading to unnecessarily long treatments and side effects. Recent research suggests that RTX also impacts CD8+ T-cells, which could serve as valuable markers for better disease monitoring.

The main goal of the NALVANCA cohort is to identify biomarkers within these CD8+ T-cells. Researchers aim to find biological signals that respond to treatment and can predict a relapse. By studying these markers at the start of therapy and during the immune recovery phase, the study hopes to personalize treatment duration and management for each patient.

Recruitment targets adult patients diagnosed with ANCA-associated vasculitis. Participants must provide written informed consent for the use and storage of their blood samples in a biocollection. The protocol involves long-term monitoring with regular sampling to track changes in immune cells alongside the patient's clinical health.

研究概览

研究类型

观察性的

注册 (估计的)

120

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Loire-atlantique
      • Nantes、Loire-atlantique、法国、44093

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

取样方法

非概率样本

研究人群

The study population includes adults treated in Nantes, Saint-Nazaire, or La Roche-sur-Yon for ANCA-associated vasculitis (GPA or MPA). These patients, positive for anti-PR3 or anti-MPO antibodies, are recruited during a flare or relapse and receive Rituximab therapy. Samples are provided by the NALVANCA Biocollection.

描述

Inclusion criteria :

  • Adult patient (age ≥ 18 years).
  • Patient affiliated with the French social security system.
  • Seropositive ANCA-associated vasculitis (AAV) (positive for anti-PR3 or anti-MPO) meeting the Chapel-Hill classification criteria.
  • Patient scheduled to receive rituximab (RTX) maintenance therapy (500 mg every 6 months) following an initial flare or a relapse of the disease.

Exclusion Criteria:

  • Patient unable to provide informed consent.
  • Patient refusing to participate in the study.
  • End-stage renal disease.
  • Progressive neoplasia (excluding cutaneous carcinomas)

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

队列和干预

团体/队列
干预/治疗
NALVANCA Cohort - ANCA-associated vasculitis patients treated with Rituximab.
This cohort follows adult patients with ANCA-associated vasculitis, a systemic autoimmune disease. The intervention of interest is Rituximab (RTX) therapy, used to induce B-cell depletion. The study involves longitudinal monitoring with the systematic collection of biological samples at key time points: before treatment induction, during the depletion phase, and upon immune reconstitution (2 years after the last injection or at relapse). The objective is to study the pleiotropic effects of B-cell depletion on CD8+ T-cells to identify biomarkers capable of predicting the risk of relapse.
systematic collection of additional biological samples (blood volume)
BVAS (Birmingham Vasculitis Activity Score) and VDI (Vasculitis Damage Index) are standardized clinical assessment tools used in vasculitis studies. BVAS is a physician-reported score that evaluates current disease activity across organ systems, capturing the presence and severity of active vasculitic manifestations. In contrast, VDI measures accumulated and irreversible organ damage resulting from vasculitis and/or its treatment over time, irrespective of current disease activity. Together, these instruments allow comprehensive evaluation of both disease activity and long-term patient outcomes in clinical trials.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Identification of a CD8+ T-cell signature sensitive to B-cell depletion.
大体时间:From diagnosis up to 2 years after the final rituximab infusion
Identification of a CD8+ T-cell biomarker demonstrating dual sensitivity: during rituximab-induced depletion (pre- vs. post-RTX comparison) and during immune reconstitution (comparison of samples under treatment vs. 2 years post-treatment or at relapse).
From diagnosis up to 2 years after the final rituximab infusion

次要结果测量

结果测量
大体时间
To characterize the relationship between B-cell immune responses and CD8 T-cell responses in patients with ANCA-associated vasculitis.
大体时间:From diagnosis up to 2 years post-treatment.
From diagnosis up to 2 years post-treatment.
To identify potential immune biomarkers associated with disease phenotype and outcomes, including CD4 T-cell subsets, regulatory T cells (Tregs), innate lymphoid cells, immunoglobulins, and inflammatory markers.
大体时间:From diagnosis up to 2 years post-treatment.
From diagnosis up to 2 years post-treatment.
To evaluate the association between lymphocyte-related immune biomarkers and the occurrence of intercurrent clinical events, including infectious and cardiovascular complications.
大体时间:From diagnosis up to 2 years post-treatment.
From diagnosis up to 2 years post-treatment.

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Nicolas Degauque, PhD、CR2TI - UMR1064 (INSERM)

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年9月1日

初级完成 (估计的)

2051年9月1日

研究完成 (估计的)

2051年9月1日

研究注册日期

首次提交

2026年6月4日

首先提交符合 QC 标准的

2026年6月4日

首次发布 (实际的)

2026年6月9日

研究记录更新

最后更新发布 (实际的)

2026年7月7日

上次提交的符合 QC 标准的更新

2026年7月3日

最后验证

2026年7月1日

更多信息

与本研究相关的术语

关键字

其他研究编号

  • RC19_0417
  • 2026-A00620-51 (其他标识符:ANSM)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

未定

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅